Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer

In a prospective Hong Kong screening study of 20,174 asymptomatic participants, plasma EBV DNA identified 34 nasopharyngeal carcinomas, with 97.1% sensitivity, 98.6% specificity, and a higher fraction of stage I–II disease than a historical cohort (71% vs 20%).

N Engl J MedPubMed 28792880DOI 10.1056/NEJMoa1701717